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Abstract
Background: Depression is a condition with various modes of
treatment, including pharmacotherapy, psychotherapy, and some
combination of each. The role of psychotherapy in the treatment of
depression relative to the role of pharmacotherapy is not well
understood, and guidelines for psychotherapy in the primary care
setting differ from guidelines for specialty care. There is little
evidence concerning circumstances in actual practice that affect the
use of psychotherapy in conjunction with pharmacotherapy.
Aims of the Study: We retrospectively identify the most important
factors associated with the use of psychotherapy in combination
with pharmacotherapy in the treatment of depression. Specifically,
we study provider choice, health plan characteristics, and patient
characteristics.
Methods: We use a comprehensive medical and pharmacy claims
data sample of 1,023 individuals during 1992–1994. We select
persons prescribed with an antidepressant medication and diagnosed
with a depressive disorder by a primary care physician, psychiatrist,
or non-physician mental health specialist. Controlling for depression
diagnosis, comorbidity, and demographics, we examine the role of
provider type and insurance plan benefit characteristics. We study
the intensity of psychotherapy using zero-inflated count regression,
the intensity of pharmacotherapy using truncated count regression,
and the likelihood of treatment failure using logistic regression.
Results: Patients initially seeing a psychiatrist receive more
than double the amount of psychotherapy and slightly more
pharmacotherapy than patients of other providers. An additional
prescription for antidepressant medication reduces by five percent
the likelihood of treatment failure, but the amount of psychotherapy
does not affect treatment failure. Patients seeing a psychiatrist are
half as likely to have failed treatment, independent of any effect of
psychotherapy. Case management and coinsurance rates do not
affect the amount of psychotherapy, but the presence of case
management positively affects the amount of pharmacotherapy and
the likelihood of treatment failure.
Discussion: Although the amount of psychotherapy provided in
conjunction with medication does not lower the rate of treatment
failure, psychotherapy may nonetheless provide beneficial outcomes
not studied here. Choice of a psychiatrist reduces the likelihood of
treatment failure, independent of the number of psychotherapy
sessions and antidepressant prescriptions. The effect of provider choice
on treatment failure could be an artefact of differences in provider
follow-up practices or could represent a difference in provider skills.
Managed care strategies do not appear to reduce the intensity of
depression treatment, but case management does increase the
likelihood of treatment failure.
Implications for Health Care Provision: Combined treatment with
pharmacotherapy and psychotherapy appears to be individualized, as
there is no pattern of more or less psychotherapy associated with
antidepressant medication use. Choice of psychiatrist as the initial
provider appears to reduce the likelihood of treatment failure,
suggesting coordinated care may be beneficial. The link between
psychiatrists and more psychotherapy is consistent with the
hypothesis that patients resistant to treatment may nonetheless
receive high quality care.
Implications for Health Policies: Managed care tools such as case
management and coinsurance rates do not appear to restrict the use
of either psychotherapy or pharmacotherapy. The association of case
management with an increased likelihood of treatment failure
suggests that plan characteristics can affect outcomes.
Implications for Further Research: Our study focuses on
psychotherapy combined with medication and does not consider
psychotherapy alone in the treatment of depression, which may be a
preferred mode of treatment for some. Outcomes other than
treatment failure, as well as costs, should also be considered. Our
findings that psychiatrists are associated with a decreased likelihood
of treatment failure and that case management is associated with an
increased likelihood of treatment failure despite a correlation with
greater pharmacotherapy intensity present avenues for additional
study.
Received 1 October 2002; accepted 8 February 2003
Introduction
The role of psychotherapy in the treatment of depression
has been a subject of some uncertainty in recent years as
pharmacotherapies have proliferated. The proportion of
people treated with psychotherapy has declined even though
Electronic copy available at: http://ssrn.com/abstract=1809038
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the rate of outpatient treatment for depression has increased.1
Although psychotherapy alone is recognized as an efficacious
treatment, it is often provided in combination with
antidepressant medication in the treatment of depression. We
examine how pharmacotherapy and psychotherapy are
combined in practice across providers in the treatment of
depression and the ultimate consequences of the mix of
pharmacotherapy, psychotherapy, and provider for depression
treatment failure.
Psychotherapy in conjunction with medication may be
beneficial not only as a direct treatment of the depressive
disorder and its symptoms but also as an aid both to
medication compliance2 and family support of treatment.3
Although combined treatment has been shown to be more
efficacious than unimodal treatment in specific contexts,4
generally the indications for combination treatment are
unclear, and guidelines for treatment in the primary care
setting differ from guidelines for psychiatric specialty care.5
The most recent treatment guidelines for depression
treatment state that combined pharmacotherapy and
psychotherapy “may be a useful initial treatment choice” for
patients with moderate to severe major depression who
experience psychosocial or interpersonal problems or a
comorbid psychiatric disorder, as well as for patients with less
severe depression if they prefer combined treatment, have a
history of partial response to psychotherapy or medication
alone, or exhibit poor adherence to treatment.6 However, there
is no model for combined treatment, and the optimal frequency
of psychotherapy as part of a treatment plan has not been
determined. Several individual-specific factors are relevant in
determining the frequency of psychotherapy visits, including
the goals of the individual treatment plan, the maintenance of
successful therapeutic relationship, the patient’s adherence to
treatment, and suicidality.6
The circumstances in actual practice under which
psychotherapy is best combined with antidepressant
medication are not well understood. Aside from provider and
patient preferences, additional factors can affect the use of
psychotherapy, such as availability and cost.7 Previous work
has identified a need for examination of the practice of
psychotherapy, including psychotherapy with concurrent
pharmacotherapy, as well as characterization of patients in
terms of diagnosis, severity, comorbidity, and demographics.8
Other work has suggested that characteristics of the health
care system can affect the use of psychotherapy in treating
depression. Data from the Medical Outcomes Study showed
that depressed patients of general medical clinicians receive
less counseling than patients of mental health specialists and
that health plan prepayment is associated with lower counseling
rates.9 Although the cost-containment incentives of managed
care organizations have been cited as a potential reason for
reductions in the use of psychotherapy, some observers have
suggested that psychotherapy, if shown to be cost-effective,
might be more compatible with managed care than with
traditional health insurance arrangements.10 Indeed, in the
context of severe mental illness, psychotherapy has been
associated with reduced costs.11 Thus, the relationship between
the use of psychotherapy and managed care strategies is not
clear.
Recent evidence suggests that psychotherapy and
pharmacotherapy are productive complements in treating
depression, meaning that they have similar therapeutic effects,
ceteris paribus.12 However, in clinical practice they need not
be used in isolation (as therapeutic substitutes in depression
treatment), but rather together (as complementary treatments).
Using a claims data sample of persons diagnosed with
depression and receiving a prescription for an antidepressant
medication we attempt to identify retrospectively the most
important factors associated with the use of psychotherapy in
combination with medication in the treatment of depression.
Our results suggest that patients initially seeing psychiatrists
get substantially more psychotherapy and slightly more
pharmacotherapy than patients initially seeing other non-
psychiatrist providers of anti-depression care. We find no
evidence that the two types of therapies are used in
conjunction systematically or that more of one is used in place
of less of the other therapy in depression treatment involving
some pharmacotherapy. Concerning the downstream benefits
of pharmacotherapy and psychotherapy, our results indicate
that pharmacotherapy lessens the likelihood of failed
depression treatment and that psychotherapy does not have an
independent effect on treatment failure; however patients
seeing a psychiatrist are less likely to have a failed treatment,
net of any effect of the amount of psychotherapy.
Methods
Our objective is to disentangle the relative quantitative
importance of factors influencing the intensity of psychotherapy
in individuals treated for depression with antidepressant
medication. We use a retrospective claims database of
persons diagnosed with depression and treated with
antidepressant medication with or without psychotherapy.
Using multivariate statistical models that are appropriate for
dependent variables that take on non-negative integer values
and that may also be truncated, we assess whether the factors
influencing psychotherapy are jointly determined with the
intensity of medication use. Finally, we examine the
relationship among psychotherapy, pharmacotherapy, and a
downstream outcome of interest in the treatment of
depression, the likelihood of treatment failure.
Data and Variable Definitions
Our data, which come from the MarketScan™ database,
contain comprehensive medical and pharmacy claims data for
about 700,000 employed persons and their families who
worked in 20 different self-insured Fortune 500 companies
(The MEDSTAT Group, Ann Arbor, MI). Health insurance
benefits offered by employers include indemnity and managed
care plans that were dominated by preferred provider
organizations. The particular MarketScan™ information
we use centers on claims data for continuously enrolled
individuals and their plan benefit information during 1992-
1994.
Available claims information covers eight quarters post-
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depression diagnosis and two quarters pre-depression
diagnosis. We select antidepressant recipients diagnosed
with a depressive disorder by a primary care physician, a
psychiatrist, or a non-physician mental health specialist. To
identify new treatment episodes we exclude persons with any
claims for psychotherapy or antidepressants in the six-month
period prior to the diagnosis of depression. We include only
people with information about their plan. The final sample
size we use in estimation is 1,023.
Table 1 lists the variables of interest in the study sample. In
addition to demographic information about the patient’s age,
sex, and the number of comorbid physical conditions, we
examine effects of the specific depression diagnosis and the
type of provider associated with the initial depression
diagnosis. We also attempt to account for propensity to use
health care and overall health by including non-psychiatric
costs in the quarter prior to the diagnosis. We account for the
intervening influence of the number of anxiolytic prescriptions
filled after the depression diagnosis.*  To examine the effect
of characteristics of the health plan and to purify the estimated
effects of provider on outcomes of interest in a multivariate
setting, we include as control variables the outpatient
Table 1. Descriptive statistics stratified by provider - Mean (standard deviation)
Non-Physician
Mental Health Primary Care
Psychiatrist Specialist Physician
Variable Total (n = 272) (n = 163) (n = 588)
Psychotherapy Visits 5.727 10.882 5.098 3.517
(10.262) (12.726) (8.630) (8.409)
Antidepressant Prescriptions 11.413 12.456 11.123 11.010
(9.255) (9.815) (9.459) (8.903)
Anxiolytic Prescriptions 2.895 4.272 3.160 2.185
(7.658) (9.905) (9.953) (5.299)
Treatment Failure 0.223 0.154 0.233 0.252
(0.416) (0.362) (0.424) (0.434)
4+ Antidepressant Prescriptions 0.765 0.739 0.785 0.772
(0.424) (0.440) (0.412) (0.420)
Log Medical Costs 8.031 8.035 8.260 7.966
(1.341) (1.545) (1.171) (1.277)
Age 42.642 42.188 41.865 43.068
(9.335) (10.087) (8.336) (9.227)
Female 0.738 0.665 0.724 0.776
(0.440) (0.473) (0.448) (0.418)
Major Depression, Single Episode 0.179 0.313 0.135 0.129
(0.383) (0.464) (0.343) (0.336)
Major Depression, Recurrent 0.109 0.265 0.141 0.029
(0.312) (0.442) (0.349) (0.168)
Dysthymia 0.264 0.313 0.460 0.187
(0.441) (0.464) (0.500) (0.390)
Reactive Depression 0.077 0.066 0.239 0.037
(0.267) (0.249) (0.428) (0.190)
Depression NOS 0.370 0.044 0.025 0.617
(0.483) (0.206) (0.155) (0.486)
Log Pre-Diagnosis Costs 4.568 4.301 4.892 4.602
(2.622) (2.836) (2.686) (2.490)
Comorbidities 6.829 6.688 7.190 6.794
(2.992) (3.182) (2.856) (2.934)
Mental Health Coinsurance Rate 0.126 0.140 0.120 0.121
(0.095) (0.121) (.087) (.083)
Case Management 0.362 0.379 0.288 0.374
(0.481) (0.486) (0.454) (0.484)
* Anxiolytic medication is intended to reduce anxiety and could correspond
to the level of psychiatric distress, be an indicator of the patient’s propensity
or willingness to fill prescribed medication, be used by the patient as a
hypnotic (perhaps to counteract a side effect of antidepressant
pharmacotherapy), or indicate inappropriate treatment of depressive
symptoms.
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psychiatric coinsurance rate and whether the health plan
employed case management practices.*  We consider there to
be treatment failure when the claims data include any of the
following: a new episode of drug therapy follows a gap of six
or more months in medication claims, a suicide attempt, a
psychiatric hospitalization, a mental health related emergency
department visit, or electroconvulsive therapy.†
Data Analytic Procedures
To study the use of psychotherapy and pharmacotherapy in
some quantitative detail we expand on simple univariate
comparisons in by employing multivariate models of the
number of psychotherapy visits and antidepressant
prescriptions that account for the substantial number of
nonusers of psychotherapy and the fact that all patients had at
least one antidepressant prescription. Our list of categorical
explanatory variables includes depression diagnosis
indicators, with Depression Not Otherwise Specified as the
reference category, and diagnosing provider indicators, with
Primary Care Physicians as the reference category. The amount
of psychotherapy is the number of psychotherapy visits after
the depression diagnosis, and  the amount of pharmacotherapy
is the number of antidepressant prescriptions. Because the
dependent variables we study are each a non-negative integer
we use count data models rather than standard regression
models in which the dependent variable is a continuous
variable.*
The Poisson regression model is the most basic count model,
but it invokes the restriction of equality between mean and
variance, termed equi-dispersion. Because preliminary results
show that the conditional mean and variance are unequal for
each of the two therapies we study in our sample, we employ
the more general Negative Binomial multivariate model, which
is a generalization of the Poisson model that allows for
overdispersion (the conditional variance exceeds the
conditional mean) and has been productively applied to
models of health care utilization.15-18
Expressed algebraically, the conditional mean value of a
therapy level in a sample where i indexes a case of depression
is
  ( | ) exp( )i i i iE y x b xλ ′= = ,     (1)
where b is the vector of parameters to estimate that determine
the marginal effect of an independent variable, x, on the
discrete value of therapy incidence, y. The negative binomial
count model also includes an overdispersion parameter, δ, hat
parameterizes the prevalent form of heteroskedasticity where
the conditional variance exceeds the conditional mean, λ, which
is prevalent in count data
    var( | ) (1 )i i i iy x λ λ δ= + . (2)
Equation (2) illustrates how the negative binomial
specification nests inside it the Poisson model, and that
if           then the Poisson count model appears.
An additional complexity common in models of counts is a
large number of zero values. In our case, about 47 percent of
the sample had no claim for psychotherapy, and we attempt to
account for the high proportion of patients not receiving
psychotherapy in the statistical model. Although the Negative
Binomial model accommodates a large number of zeros, we
also estimate variations of the Negative Binomial model that
further adjust for so-called excess zeros in the sample termed
the zero-inflated Negative Binomial model. The ZINB model
adds what is termed a splitting parameter, q, that is the
proportion of zero use that will occur no matter what the
values of the independent variables might be (some people
will never submit to psychotherapy)
 ( | ) (1 ( ))i i i iE y x q xλ= − (3)
and
              var( | ) (1 )[1 ( )]i i i i i iy x q qλ λ δ= − + + . (4)
Using the same list of explanatory variables we also
examine models of the intensity of pharmacotherapy for
depression where the dependent variable is the number of
antidepressant medication prescriptions filled. To expand on
a simple comparison of means we again use a multivariate
count regression model. However, because our sample of
depressed persons is constructed by locating patients with at
least one antidepressant prescription, we must employ a model
that accounts for truncation at zero.*  We use a truncated
negative binomial model to examine the marginal effect of
provider type on anti-depressant medication use.
Along with the count regressions for psychotherapy, our
regression for pharmacotherapy reveals whether intensity of
pharmacotherapy seems to complement, substitute for, or is
largely independent of the amount of psychotherapy. If
psychotherapy complements pharmacotherapy, then the
number of psychotherapy visits should increase with the
number of antidepressant prescriptions. If they are substitutes,
then the number of psychotherapy visits should decline as the
number of prescriptions increases. If neither a positive nor a
negative relationship occurs between the two therapies, then
we consider decisions to use psychotherapy and
pharmacotherapy as largely independent.
* In the MarketScanTM data we use the term case management describes a
form of utilization review and not clinical case management often applied to
the care of persons with severe mental illnesses such as schizophrenia. The
goal of the case management practices as examined here is most likely to be
reduction or limitation of unnecessary treatment.
† For another example of a similar claims-based method of identifying
treatment failure (relapse) see (13), who find that about three-fourths of
treatment failures were due to starting a new episode of anti-depressant
treatment.
* OLS is clearly a misspecified functional form as the dependent variable is
both bounded and bunched at zero. Alternatives to count models include
ordered probit, Tobit, or an exponential functional form estimated with non-
linear least squares. For empirical examples see14 and for discussion of the
relative strengths and weakens of alternative models see.15
* Adjusting for truncation involves rescaling the likelihood that the
pharmacotherapy dependent variable takes on any particular value by the
inverse of the probability of y > 0.19
ˆ 0δ =
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Lastly we examine the relative importance of the
components of anti-depression treatment on treatment success
measured by the likelihood of a failed treatment. For ease of
interpretation we use the familiar binary ( = 0, 1) logit
specification with
Prob(Failure) = Prob(y = 1)= /(1 )x xe eβ β′ ′+ , (5)
where we are concerned with the estimates of β to use in
constructing case-mix adjusted effects of the regressors
related to the specialty of treatment provider and amounts of
pharmacotherapy versus psychotherapy. In our data failure
means that the person subsequently experienced a new
episode of anti-depressant therapy, a suicide attempt,
psychiatric hospitalization, a mental health related emergency
department visit, or electroconvulsive therapy, which is a
measure previously shown responsive to changes in the
quality of care.20,13
Before discussing our results it is important to note that the
regression coefficients, b in Equation (1) and β in Equation(5)
are not the objects of interest, because they are not themselves
the estimated effects of a unit change in an independent
variable, the so-called marginal effects. All of the models we
estimate are non-linear index transformations of the
regressors with general form                                so that marginal
effects (ME) of interest must be evaluated at a particular set of
values for x, which we generally set equal to  . For a
continuous regressor ME =       ,   so that for the negative
binomial models of pharmacotherapy and psychotherapy
ME=           and for the treatment failure logit the marginal
effect is ME =                           where P = Prob(y = 1). For a
discrete regressor (provider type),
  In the empirical results we focus the discussion on the
estimated marginal effects of provider type on the numbers of
psychotherapy visits and anti-depressant prescriptions and on
the marginal effects of the intensity of pharmacotherapy, psy-
chotherapy, and provider type on treatment effectiveness meas-
ured by the probability of a treatment failure.
Results
Table 1 presents the descriptive statistics for the entire sample
and stratified by the type of provider making the initial
diagnosis of depression. The specialty of the first provider is
significantly associated with the mix of treatment patients
subsequently receive. Patients diagnosed by psychiatrists
average about 11 claims for psychotherapy, while patients of
non-physician mental health specialists average about 5
psychotherapy claims, and patients diagnosed by primary care
physicians average 3-4 psychotherapy claims.
As another point of comparison, 90 percent of patients
diagnosed by psychiatrists have at least one psychotherapy
claim following the depression diagnosis, 54 percent of
patients diagnosed by non-physician mental health specialist
have at least one psychotherapy claim, and 35 percent of
primary care patients have at least one psychotherapy claim.
Inter-provider differences in case mix, which could
reflect diagnostic patterns or real differences in the types of
patients who seek care from specific providers, are such that
psychiatrists are the main provider of treatment for cases of
single episode and recurrent major depression while non-
Table 2. Psychotherapy visits - Zero inflated negative binomial regression
Marginal
Coefficient Std. Error t-ratio P-value Effect Std. Error t-ratio P-value
Constant 1.671 0.281 5.951 0.000 11.745 3.294 3.565 0.000
Age -0.013 0.005 -2.732 0.006 -0.094 0.065 -1.456 0.146
Female 0.104 0.118 0.879 0.380 0.731 1.389 0.527 0.599
Major Depression, Single Episode 0.090 0.159 0.564 0.573 0.629 1.862 0.338 0.736
Major Depression, Recurrent 0.657 0.210 3.135 0.002 4.620 2.458 1.880 0.060
Dysthymia 0.253 0.115 2.193 0.028 1.775 1.350 1.314 0.189
Reactive Depression 0.125 0.242 0.519 0.604 0.881 2.834 0.311 0.756
Log Pre-Diagnosis Costs 0.007 0.018 0.400 0.689 0.052 0.217 0.237 0.812
Anxiolytic Prescriptions 0.030 0.008 3.678 0.000 0.214 0.102 2.102 0.036
Comorbidities 0.010 0.018 0.562 0.574 0.072 0.217 0.333 0.739
Psychiatrist 0.950 0.201 4.737 0.000 6.676 2.353 2.838 0.005
Non-MD Mental Health Specialist 0.225 0.154 1.459 0.145 1.580 1.808 0.874 0.382
Plan Coinsurance Rate -0.444 0.621 -0.715 0.475 -3.122 7.282 -0.429 0.668
Case Management -0.069 0.099 -0.702 0.482 -0.487 1.157 -0.421 0.674
Overdispersion Parameter 2.316 0.389 5.950 0.000
Zero Inflation Parameter -0.895 0.329 -2.723 0.006
ˆˆˆ ˆ( 1) ( 0) ( ( 1))y x y x G f x= − = = =
ˆˆ ˆˆ ˆ( ( 0)) ( )(1 ( )G f x P x P x β− = ≅ −
ME =
( ( ))y G f x=
x
ˆĜ f′ ′
ˆˆ ˆ( )(1 ( )P x P x β−
ˆˆ( )x bλ
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physician mental health specialists are the main provider of
treatment for cases of dysthymia and reactive depression.
Overall, about three fourths of the sample received at least
four prescriptions in the first six months of treatment, and there
were no differences across providers. (Psychiatrist patients,
however, receive more prescriptions for anxiolytics and are
less likely to have a failed treatment than persons seeing other
providers.)
Because univariate comparisons do not reveal fully
differences in case-mix among various providers, we proceed
to control for case-mix details in order to identify better
the role of provider type in the use of psychotherapy,
pharmacotherapy and treatment failure.
Psychotherapy Visits
Table 2 presents the zero-inflated negative binomial (ZINB)
count model of the number of psychotherapy visits. We
include both model coefficients and marginal effects computed
at the means of the independent variables. Both the estimated
overdispersion parameter δ̂  and the estimated zero-inflation
parameter (which is a function of ˆiq )  are significant
statistically, which means that the data reject both the simpler
Poisson specification and the basic negative binomial
specification in favor of the ZINB count model form.*
Concerning the variables controlling for case mix across
providers, a diagnosis of recurrent major depressive disorder
is significantly and positively related to the number of
psychotherapy visits, resulting in about 4-5 additional
psychotherapy visits; the number of visits for a major
depressive disorder is about twice the mean. The effects of all
other types of depression are small and insignificant
statistically as are the influences of age and gender on
psychotherapy. Neither the psychiatric coinsurance rate nor
the presence of case management in the health insurance plan
are statistically significant predictors of the amount of
psychotherapy.*
Because provider type appears related to the subsequent
mix of treatments, a focal point of our research effort is whether
there is a statistically significant differential effect of provider,
ceteris paribus, on the use of psychotherapy. If the amount
of psychotherapy is a substitute for pharmacotherapy, then it
follows that providers who use more psychotherapy should
use less pharmacotherapy.
Adjusting for case mix, diagnosis by a psychiatrist is
associated with approximately six more psychotherapy visits
than if the diagnosis is by a primary care physician.† The
Table 3. Antidepressant prescriptions - Truncated negative binomial
Marginal
Coefficient Std. Error t-ratio P-value Effect Std. Error t-ratio P-value
Constant 1.716 0.196 8.773 0.000 18.194 5.993 3.036 0.002
Age 0.004 0.004 0.951 0.341 0.043 0.049 0.877 0.381
Female -0.016 0.084 -0.196 0.845 -0.175 0.932 -0.187 0.851
Major Depression, Single Episode 0.121 0.109 1.114 0.265 1.285 1.265 1.016 0.310
Major Depression, Recurrent 0.137 0.152 0.901 0.368 1.452 1.746 0.832 0.406
Dysthymia -0.136 0.100 -1.359 0.174 -1.438 1.216 -1.182 0.237
Reactive Depression 0.048 0.159 0.300 0.764 0.505 1.761 0.286 0.775
Log Pre-Diagnosis Costs 0.003 0.014 0.202 0.840 0.031 0.160 0.193 0.847
Anxiolytic Prescriptions 0.035 0.014 2.552 0.011 0.369 0.194 1.906 0.057
Comorbidities 0.015 0.006 2.474 0.013 0.158 0.089 1.780 0.075
Psychiatrist 0.038 0.097 0.391 0.696 0.401 1.081 0.371 0.711
Non-MD Mental Health Specialist 0.049 0.108 0.456 0.648 0.521 1.207 0.432 0.666
Plan Coinsurance Rate 0.193 0.378 0.510 0.610 2.047 4.239 0.483 0.629
Case Management 0.326 0.079 4.136 0.000 3.452 1.446 2.387 0.017
Overdispersion parameter 0.836 0.062 13.395 0.000
*  We modeled the zero generating process as a logistic function of all x’s.
Changing the list of regressors or functional form of the zero generating
process proved uninformative. The estimated zero inflation statistic in
Table 2 is the statistic21 that one uses to check the non-nested hypothesis
whether the zero-inflated negative binomial model detects excess zeros after
controlling for overdispersion.22 When the data support a ZINB model the
absolute value of the computed Vuong statistic is at least 2.0. As a point of
reference, the estimated marginal effect of a psychiatrist is about 15
percent smaller in a model where we purposely incorrectly ignore zero
inflation.
*   We note that lack of a coinsurance rate effect is driven by the fact that the
rate varies little across the patients of primary care physicians and other
mental health specialists. A separate count regression for only the patients of
psychiatrists shows a significantly negative coinsurance rate effect on
psychotherapy visits such that a doubling of the coinsurance rate leads to 25
percent fewer visits. The possibility of heterogeneity in the effect of health
care plan characteristics across providers remains an interesting issue for
future research.
† As a basic robustness check we estimated the psychotherapy model in
Table 2 using Tobit regression. The results were similar in that the estimated
marginal effect of having a psychiatrist provider was a statistically
significant 6.2 additional visits with no significant difference for non-
physician mental health specialist.
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relative therapy mix outcome is quite different for diagnosis
by non-physician mental health specialists. In contrast to the
results for psychiatrists, there is a quantitatively small but
insignificant increase in the use of psychotherapy subsequent
to an initial diagnosis by a non-physician mental health
specialist. After adjusting for case-mix, diagnosis by a non-
physician mental health specialist does not result in any
additional psychotherapy visits than does diagnosis by a
primary care physician.
The case-mix adjusted differential in the amount of
psychotherapy in Table 2 between psychiatrists and other
providers is about the same as the unadjusted difference in
Table 1; patients whose initial providers were psychiatrists
got about twice the psychotherapy as patients whose initial
providers of anti-depression therapy were general medical
practitioners or non-physician mental health specialists. Even
when faced with patients of the same age, gender, depression
type and general health, psychiatrists’ patients receive
substantially more psychotherapy than the patients of other
types of initial providers of anti-depression therapy. An
interesting question that we attempt to address shortly is
whether greater amounts of psychotherapy also reduce the
likelihood that the anti-depression treatment fails.
Anti-depressant Medication
The results for the truncated count model of anti-depressant
prescriptions appear in Table 3. The most striking result is
that the presence of case management in the health plan is
significantly associated with the number of antidepressant
prescriptions, increasing the number of prescriptions by more
than three. Using the mean as a point of reference, case
management increases the intensity of pharmacotherapy by
about 30 percent. No other covariates had a large statistically
significant estimated marginal effect as case management. The
most important result to emerge from our truncated negative
binomial count model of anti-depression pharmacotherapy is
that the case-mix adjusted results for inter-provider differences
mimic the unadjusted results of Table 1. We find no
differences across the initial provider in the amounts of
anti-depressant prescriptions that patients fill.*
Treatment Failure
One way to assess the quality of anti-depression treatment is
by examining whether a person receives any therapy at all or
discontinues therapy early, failing to complete an adequate
amount of therapy according to recommended guidelines.23, 24
Another way to meter success is to examine the downstream
consequences of therapy by noting whether a patient suffers a
treatment failure. In our data about 22 percent of patients have
a failed treatment. Table 4 presents logit coefficient estimates
for how intensity of treatment and provider type influence the
probability of treatment failure, ceteris paribus.
The most notable results concerning treatment success as
indicated by a reduced likelihood of treatment failure relate to
having a psychiatrist provider. In Table 4 we capture
Table 4. Treatment failure - Logit regression
Marginal
Coefficient Std. Error t-ratio P-value Effect Std. Error t-ratio P-value
Constant -0.322 0.449 -0.717 0.473 0.052 0.072 -0.719 0.472
Age -0.013 0.009 -1.443 0.149 -0.002 0.001 -1.445 0.149
Female -0.338 0.189 -1.790 0.074 -0.054 0.030 -1.794 0.073
Major Depression, Single Episode -0.103 0.258 -0.399 0.690 -0.017 0.041 -0.399 0.690
Major Depression, Recurrent -0.133 0.338 -0.392 0.695 -0.021 0.054 -0.392 0.695
Dysthymia 0.076 0.221 0.343 0.732 0.012 0.035 0.343 0.732
Reactive Depression 0.176 0.335 0.524 0.600 0.028 0.054 0.524 0.600
Log Pre-Diagnosis Costs -0.015 0.032 -0.466 0.641 -0.002 0.005 -0.466 0.641
Anxiolytic Prescriptions 0.036 0.011 3.261 0.001 0.006 0.002 3.267 0.001
Comorbidities 0.077 0.029 2.617 0.009 0.012 0.005 2.625 0.009
Psychiatrist -0.682 0.241 -2.829 0.005 -0.109 0.038 -2.851 0.004
Non-MD Mental Health Specialist -0.216 0.253 -0.853 0.393 -0.035 0.040 -0.854 0.393
Plan Coinsurance Rate -0.986 1.013 -0.974 0.330 -0.158 0.162 -0.976 0.329
Case Management 0.565 0.165 3.420 0.001 0.091 0.026 3.450 0.001
Antidepressant Prescriptions -0.063 0.011 -5.945 0.000 -0.010 0.002 -6.229 0.000
Psychotherapy Visits 0.004 0.009 0.510 0.610 0.001 0.001 0.510 0.610
* As a basic robustness check we also estimated the pharmacotherapy model
in Table 3 using truncated normal regression.22 The results were similar in
that there were also no statistically significant differences across providers
in the number of anti-depressant prescriptions filled.
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treatment in three dimensions: the amount of psychotherapy,
the amount of pharmacotherapy, and the type of treatment
provider. Recall that the count regression results in earlier
tables had patients of psychiatrists receiving significantly more
psychotherapy so that one way a psychiatrist could reduce the
likelihood of a failed treatment for depression is by greater
amounts of psychotherapy. The results in Table 4 reveal that,
after controlling for diagnosing provider type, the number of
psychotherapy visits does not affect the likelihood of
treatment failure.
Although the amount of psychotherapy does not affect
treatment failure, the amount of pharmacotherapy does affect
treatment failure in our data. Using the mean as a reference
point, an extra anti-depressant prescription lowers the
probability of treatment failure by about 4-5 percent (-0.01/
0.22). Because our results in Table 3 indicated no differences
in the amount of pharmacotherapy across providers, however,
there is no direct effect on treatment failure of a psychiatrist
provider through any differential amount of anti-depression
medication.
What we find is more subtle, holding psychotherapy visits
and anti-depressant prescriptions constant, having a
psychiatrist initial provider lowers the probability of a failed
treatment by almost 50 percent using the mean likelihood of
treatment failure as a reference point
(ME / P = _0.109 / 0.223 = 0.49)
In our data there appears to be a benefit of having a psychia-
trist provider in terms of reducing the chance of having a failed
treatment for depression that is over and above the measured
amounts of psychotherapy and pharmacotherapy psychiatrists
provide relative to other providers.
Discussion
Our research objectives have centered on understanding any
connections among the intensity of psychotherapy received
by depressed patients who also receive an antidepressant with
an eye for several questions of medical interest. Do there
appear to be significantly different amounts of psychotherapy
across providers, and how large are the inter-provider
differences in psychotherapy?  Is there a relationship between
intensity of psychotherapy and intensity of pharmacotherapy?
Finally, are there quantitatively important inter-provider
differences in anti-depression treatment success as measured
by the likelihood of treatment failure and how is any
difference related to inter-provider differences in the intensity
of pharmacotherapy versus the intensity of psychotherapy?
We find that after adjusting for case mix psychiatrists’
patients receive almost twice the number of psychotherapy
visits but fill no more prescriptions for anti-depressant
medication than the patients of general medical providers or
non-physician mental health specialists. In the sense that
psychiatrist’s patients get more psychotherapy than other
providers’ patients but no more or less pharmacotherapy, there
is no obvious pattern across providers for combining
pharmacotherapy and psychotherapy. It appears that decisions
regarding use of psychotherapy and pharmacotherapy are
largely independent.
Although the research presented here generally agrees with
prior research there are patterns of treatment we observe that
are also somewhat surprising. For example, although the first
treatment for depression appears to depend largely on the
specialty of the provider at the point of entry,24 among patients
receiving medication the number of visits and the number of
prescriptions appears independent of who first diagnosed a
patient’s depression. The only exception to the diagnoser-
treatment pattern is the finding that psychiatrists use more
psychotherapy than other providers; whether a patient first
entered care through a general medical doctor or through a
non-physician specialist makes no difference in the relative
amount of psychotherapy and pharmacotherapy received.
We note some limitations to our study that require careful
interpretation of the results. First is the difficulty of
identifying clinical events in claims data. We acknowledge that
unmeasured patient characteristics and diagnostic patterns
could differ systematically across providers. For example,
psychiatrists might be more likely to diagnose a patient with
recurrent major depressive disorder while a primary care
provider might be more likely to diagnose a patient with
depression NOS. Table 1 demonstrates differences in the
frequencies of diagnostic codes by provider type although our
claims data do not allow us to explore more rigorously whether
Table 1 captures case-mix differences or differences in
provider habits. If there are differences in provider
diagnosing habits then our results pertaining to diagnosis
categories actually reflect differences attributable to provider
type.
Another limitation of our study is that our data identify only
the provider that initiates the patient’s treatment by
diagnosing the depressive disorder. Our data do not identify
the provider type associated with each subsequent encounter.
Clearly, some patients in our sample are subsequently treated
by a different provider type than the one making the initial
diagnosis, whether or not they continue to see the diagnosing
provider. The most obvious case is that of a person diagnosed
by a non-physician mental health specialist, who generally does
not have the ability to prescribe medication. Persons initially
seeing a non-physician mental health provider must be referred
to other providers to receive a prescription for antidepressant
medication. Our conclusions regarding provider type are then
limited to implications about the effect of the type of provider
initiating the treatment. We believe that our results, even as
just qualified, are informative because they suggest the
importance of the provider’s role as treatment gatekeeper.
Our research has several implications for research, clinical
practice, and mental health policy. The notion that receiving
treatment from psychiatrists may be associated with
reductions in the incidence of treatment failure is provocative,
but we must acknowledge a possible confound imposed by
how treatment failure is identified here. Specifically, treatment
failure here means that a new “clean” period with no evidence
of pharmaco- or psychotherapy occurs between episodes of
medication treatment, but we could fail to observe a gap in
treatment because of the increase in the number of
_
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psychotherapy visits associated with psychiatrists. Suppose
psychiatrists are more likely to see patients intermittently in
follow up for a prior episode. If the frequency of follow-up
visits is every three months or more, then we do not observe a
“clean” period and have no opportunity to observe a treatment
failure even if one occurs clinically. Our results regarding
psychiatrists should be interpreted with caution but provide
an opportunity to investigate further the relationship between
provider type and treatment failure.
As is true for other studies that rely on MarketScan data, we
report relatively high levels of quality of pharmacotherapy.
Nearly three in four patients in our study received care
consistent with clinical practice guidelines.*  The relatively
high baseline in mind, it appears that psychiatrists are more
likely to offer additional psychotherapy to their patients. Our
findings of a link between initial provider and psychotherapy
are consistent with the hypothesis that the additional
psychotherapy may be used for patients whose symptoms are
resistant to treatment but who nonetheless may receive high
quality treatment, which is another line of research to pursue.
About a third of the plans we study used case management,
which is associated with more prescriptions. Because the case
management identified in MarketScan represents a form of
utilization review designed to limit care to persons most in
need, we hypothesize that plans who make use of the case-
management cost-containment tool may also use quality
improvement strategies that improve care. Because we cannot
explicitly control for depression severity in our study, our
finding of a positive correlation between case management
and the probability of treatment failure might suggest that plans
target case management toward patients who are more severely
depressed and likely to have a failed treatment. Our finding of
a positive link between case management and pharmacotherapy
intensity represents both an opportunity for research and an
example for clinical practice.
Finally, we point to the finding that pharmacotherapy and
psychotherapy appear to be used independently and not as
substitutes or complements among patients with some
pharmacotherapy. Because the two treatments have similar
efficacy rates, economists have tended to view them as perfect
substitutes. We suggest that physicians appear to apply the
two therapies on an individual basis, perhaps attempting to
individualize treatment based on need and patient preferences,
a worthy if difficult goal.
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